In this video, Barbara Blodi, MD, discusses results from the ARCHER trial presented at the American Society of Retina Specialists annual meeting.
The data from the phase 2 clinical trial indicate that ANX007 (Annexon Biosciences), a selective inhibitor of C1q, may show a protection from vision loss in patients with geographic atrophy, according to Blodi, professor in the department of ophthalmology and visual sciences at the University of Wisconsin School of Medicine and Public Health.
“They’re really looking at that as an important functional outcome rather than solely the growth